ArticleMicrobiology spectrum2026
Effect of oral beta-lactam dosing on outcomes of bacteremic Gram-negative urinary tract infections: a real-world analysis.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among 452 adult patients with Gram-negative bacteremia from a urinary tract infection source who received oral step-down therapy with highly bioavailable oral beta-lactam, we observed no difference in 60-day recurrence in patients treated with higher consensus-recommended dosing compared to lower, standard dosing (odds ratio = 0.76 [95% confidence interval = 0.43-1.32]), although the directionality of the effect was favorable. The study was limited by inadequate sample size and confounding. Randomized or large observational comparative effectiveness studies are needed.IMPORTANCEDefinitive treatment of Gram-negative bacteremia with oral antibiotic agents is not one size fits all. Use of oral fluoroquinolones and sulfamethoxazole/trimethoprim is evidence-based but carries risk for adverse events. Data supporting the use of oral beta-lactams are mixed, likely in part due to variable agent selection and dosing. This analysis shows that higher, consensus-recommended dosing of highly bioavailable beta-lactam antibiotics was not significantly different from patients treated with lower dosing on 60-day recurrence. Our study was limited by the number of patients with discrete MICs and overinfluence of complicated urinary tract infection on outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.